To test this hypothesis using cancer cell lines identified in the present study to be less sensitive to fadraciclib, we determined the effects of fadraciclib combined with BCL2 inhibitor venetoclax (ABT-199), or BCL2/BCL2L1/BCL2L2 (bcl-w) inhibitors ABT-263 or ABT-737 in THP-1 (Fig 6B). Here, BCL2L1 is linked to cancer.